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SummARy
UK guidelines for treating people diagnosed with 
schizo phrenia currently emphasise the primacy of 
antipsychotic medication, with or without psycho-
socially based interventions as circumstances 
dictate. We now see increasing calls, most notably 
from mental health service users, for the provision 
of ‘whole-person-based’, minimal-medication 
approaches to treating people with this diagnosis. 
This article is intended to locate the development of 
such approaches within the history of modern and 
pre-modern psychiatry and, in doing so, summarise 
the available evidence base that underpins their 
efficacy. 
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Patient choice sits at the heart of current health policy 
in the UK (Department of Health 2003, 2008) and 
has been cited as a vital component of an evidence-
based and patient-centred mental healthcare system 
(Fulford 1996; Department of Health 1999; Hope 
2002). It could be argued that the concept of choice 
underpins informed consent to treatment, in that 
consent can perhaps only be said to be properly 
informed if a person appreciates that there are choices 
available to them (Grisso 1995; General Medical 
Council 1998). Conventional medical treatment of 
people diagnosed with schizophrenia continues to 
rely almost entirely on the (sometimes involuntary) 
use of antipsychotic medication. Nowhere is this 
more clearly adumbrated than in the National 
Institute for Health and Clinical Excellence (NICE) 
guidelines for treating schizophrenia (National 
Institute for Clinical Excellence 2002), which state 
that ‘during an acute episode, antipsychotic drugs 
are necessary’ (our italics), a mandate not extended 
to psychosocial interventions. 
Our aim in this article is to consider the potential 
choices available to people diagnosed with schizo-
phrenia who may be averse to an openly medical 
(and hence psychopharmacological) approach to 
treatment. We use the term ‘potential’ pointedly in 
this context because at present there is a dearth of 
substantive alternatives to orthodox biomedical 
treatment for people diagnosed with schizophrenia 
in the UK, a situation at odds with that in several 
other countries, most notably Germany, Finland, 
Sweden and the USA (Statsny 2007).
First, a note about terminology. ‘Schizophrenia’ 
is a thoroughly contested concept with many well-
rehearsed arguments for and against its validity and 
utility. However, all of the studies conducted within 
the era of modern psychiatry, and cited in this 
article, use the term schizophrenia to describe the 
experiences of their participants. Although we might 
prefer the term ‘psychosis’, current mainstream 
psychiatric thought understands the two constructs 
as being qualitatively different. In the interests of 
exposition and communication we use the term 
schizophrenia throughout this article.
The view from now
At first glance, the case for the continuing primacy 
and necessity of antipsychotic medication in the 
treatment of people diagnosed with schizophrenia 
appears unassailable. There is a wealth of empirical 
evidence extending over many decades suggesting 
that antipsychotic medication produces significant 
improvements in schizophrenia symptoms (Davis 
1976, 2003), prevents relapse (Hogarty 1974) and 
forestalls the problem of a long duration of untreated 
psychosis (Loebel 1992). However, there is some 
doubt about the consistency of these results and the 
nature and sustainability of longer-term outcomes 
(Bentall 2002; Moncrieff 2003). Over time, manifold 
problems emerge, such as non-concordance (Oehl 
2000), treatment resistance (Kane 2007) and 
multifarious unpleasant, distressing and potentially 
life-threatening side-effects (Zarate 2001; Hennessy 
2002). The second-generation or so-called atypical 
antipsychotics were introduced in an attempt to 
obviate some of the more distressing side-effects 
caused by the first-generation drugs. However, it is 
increasingly becoming apparent not only that they 
too engender negative side-effects, but that their 
putative increased efficacy has been overstated 
(Lieberman 2005; Jones 2006). Other research 
suggests that people diagnosed with schizophrenia 
may respond better to psychosocial treatment 
or a placebo than medication (Bola 2002, 2006) 
and that those who remove themselves from 
the psychiatric system, foregoing exposure to 
antipsychotic medication, may actually have greater 
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rates of recovery (Harrow 2005) and better global 
functioning (Harrow 2007) than those who remain 
in the system. 
User feedback
Going further, service users have questioned the 
emphasis given to medication wedded, as it almost 
invariably is, to a biomedical framing of their 
experiences (Rogers 1998). They have complained 
that side-effects such as loss of motivation, sexual 
dysfunction, weight gain, drowsiness and restlessness 
(problems not always prevented by, and often 
associated with, atypical antipsychotic medication) 
are more troubling than extrapyramidal side-effects 
(Day 1997) and have argued that medication can 
actually impede or prevent healing, learning and 
recovery (Statsny 2007). Consequently, service users 
consistently call for alternative treatments that 
make antipsychotic medication less central and just 
one of many possible treatment choices (Podvoll 
2003; Agar-Jacomb 2006; Gray 2006). These calls 
have resonated with a growing interest among 
mental health professionals exploring alternatives 
to current provision within the context of greater 
patient choice (Read 2004; Lewis 2005). 
New ways of thinking
Finally, critiques of the philosophical assumptions 
underpinning the biomedical approach to the treat-
ment of schizophrenia have begun to gain traction. 
For example, the canonical view of the nature of 
schizophrenia suggests a disease of the brain 
(Hyman 1998). Given this assumption, we might 
sup pose that methodological reductionism (Box 1) 
would be the most useful approach to understand-
ing schizophrenia – seeking to know the disorder 
through garnering more and more information about 
the function and dysfunction of affected brains. 
Indeed, this seems to have been the case throughout 
the history of modern psychiatry (Griesinger 1868; 
Pincus 1993; Moncrieff 2001) and, in particular, 
during the closing decades of the 20th century, a 
period that witnessed major technological advances 
in the neurosciences (Calton 2009). 
However, there are certain problems inherent 
in this approach. First, attempting to understand 
a psychological experience solely by studying the 
brain commits the ‘mereological fallacy’ (Bennett 
2003), that is, the act of ascribing to the constituent 
parts of a thing attributes that logically apply only 
to the whole. Hence, attempting to understand 
the human experience of schizophrenia requires 
reference to psychological predicates (distress, 
persecutory thoughts, hallucinations), yet these 
apply only paradigmatically to the human being 
as a whole (it is illogical, given our current level 
of neuroscientific understanding, to talk of a brain 
hallucinating or feeling distressed). It follows that 
if the understanding of a human experience such 
as schizophrenia requires an interest in the whole 
person, then any attempt to help that person that 
relies on the use of the above predicates demands a 
similar approach. However, conventional biomedical 
treatment for people diagnosed with schizophrenia 
relies almost entirely on medication designed solely 
to affect brain function, thereby treating a part of 
the person and not the whole. 
Second, the recent interest in neuroscientific 
accounts of schizophrenia (Calton 2009), particularly 
those emanating from functional neuroimaging, 
appears, at least to some extent, predicated on the 
assumption that there is something novel or exciting 
about demonstrating that the brain is involved in 
human experiences called mental illnesses. We won-
der whether this may reflect a deeply sedimented 
Cartesian dualism wherein mind and body (brain) 
comprise two different and ineluctably separate 
substances (Descartes 1637). In this ordering of the 
world it would be astounding to show that a mental 
disorder such as schizophrenia can influence the 
brain (and vice versa). However, most contempor-
ary philosophers of mind would probably draw 
back from a dualist approach to consciousness, 
instead preferring to see it as an embodied 
phenomenon, attendant on, but not exclusive to, the 
brain (Rose 2006).
A deeper understanding of experience
In effect, we perhaps should not be so ready to stand 
in awe of prettily coloured images of brains claiming 
to represent particular states of mind. Of course the 
brain is involved in those aspects of conscious expe-
rience described as mental illnesses, but it does not 
follow that this experience can or should be wholly 
accounted for by reference to brain activity alone. 
Consequently, it might seem a little misguided to 
place undue emphasis on treating mental disorders 
such as schizophrenia by using interventions (such 
as antipsychotic medication) that are designed 
solely to alter brain activity. Further more, we might 
imagine that alternative, minimal (or no) medication 
Box 1 Reductionism
Methodological reductionism assumes that to understand 
something you have to render it down to its constituents, 
then individually scrutinise these (elements, molecules, 
cells, neural circuits, etc.) and their properties. The 
idea is that once the constituents have been thoroughly 
investigated, an understanding can be reached as to how 
they might interact to create the original system if it were 
re-formed.
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approaches, which perhaps more readily embrace 
the idea of treating the whole person (and thus 
neither commit the mereological fallacy nor reduce 
human experience simply to brain function), could 
potentially be at least as effective as antipsychotic 
medication in tend ing the distress sometimes 
associated with schizophrenia. 
What follows is a review of approaches to treating 
schizophrenia using no or minimal antipsychotic 
medication. Owing to our interest in trying to 
understand the potential efficacy and utility of 
the whole-person approach, we include only those 
studies that immersed their participants in a holistic 
therapeutic milieu. Therefore, we excluded treatment 
studies that were based solely on psychodynamic 
or cognitive–behavioural approaches because, like 
medication, these are arguably designed to influence 
specific aspects of human consciousness, such as 
intra-psychic processes or cognitive schema.
Historical evidence from the distant past
Community care
Modern psychiatry is but a fragment of the history 
of madness (Porter 2002). The treatment of schizo-
phrenia with antipsychotic medication is, therefore, 
a modern phenomenon and one standing atop and 
alongside other, older traditions of thought and 
practice. For 700 years people who have experienced 
what modern psychiatry now terms schizophrenia 
have lived as members of the community in Geel, 
a city in Belgium (Goldstein 2003). Prior to (and 
during) the period in which the use of antipsychotic 
medication was becoming popular in the West, ‘the 
mad’ would be housed with local families; these 
boarders would be assimilated into the family 
structure, receiving support and care that allowed 
them to function in the ‘normal’ social world despite 
the emotional distress that some experienced. 
Research in the modern era suggests that the Geel 
foster-family approach works because it stands 
apart from the biomedical model, with its emphasis 
on diagnosis and treatment using medication 
(Pierloot 1981). 
Self-help
Likewise, the ‘moral treatment’ developed at the 
York Retreat by William Tuke towards the end 
of the 18th century emanated from outside the 
ambit of medicine in response to the brutality of 
con temporaneous treatments (Digby 1985). This 
non-medical approach encouraged the exercise of 
residents’ self-control rather than punishment, strove 
for peace, respect and dignity in all relationships, 
and emphasised the importance of maintaining 
usual social activities, work and exercise (Warner 
1997). Contemporary data suggest that mortality at 
The Retreat was low compared with other asylums 
and its recovery rate of 54.5% for first admissions 
also compared favourably (Digby 1985). It may seem 
strange to discuss such supposedly outmoded tradi-
tions of thought and practice in a journal entitled 
Advances in Psychiatric Treatment, yet we argue that 
these approaches, predicated as they were on a 
gentle and humane engagement with the vagaries 
of human experiences at the limits, and invoking 
respect, dignity, collective responsibility and an 
emphasis on interpersonal relationships as guiding 
principles, retain an immediacy and relevance for 
the contemporary treatment of schizophrenia. 
Evidence from the past 50 years
The Soteria paradigm
In the late 1960s and early 1970s, there were a 
number of attempts to create alternatives to ortho-
dox medication and hospital-based treatment for 
people diagnosed with schizophrenia (Cooper 1967; 
Burston 2000). These initiatives cohered around a 
non-medical understanding of schizophrenia as con-
stituting an important and thoroughly meaningful 
aspect of an individual’s life history. Contrary to 
the received wisdom of the day, the use of anti-
psychotic medication was marginalised, with an 
emphasis instead on enabling individuals to go 
through their experience of psychosis with minimal 
interference and high levels of support (Pullen 1999). 
Relatively well-known UK-based initiatives included 
Kingsley Hall, associated with R. D. Laing and 
colleagues (Barnes 1971) and Villa 21, associated 
with David Cooper (Cooper 1967). These ventures 
inspired interest at an international level and 
catalysed the development of similar pro grammes 
in other countries. Among these ‘second-generation’ 
alternatives was the Soteria paradigm, initially 
developed by Mosher and colleagues in the USA 
(Mosher 1999) and then replicated, albeit in a 
slightly modified form, in Switzerland by Ciompi 
and colleagues (Ciompi 1992). Several detailed 
expositions of the paradigm are available (Warner 
1997; Mosher 2004a,b; Watkins 2006).
The Soteria paradigm encompasses both 
theoretical and practical elements that over time 
have accreted into the ‘Soteria critical elements’ 
(Aderhold 2007), which are summarised in Box 2.
At the paradigm’s core is the strong assumption 
that a person diagnosed with schizophrenia should 
be engaged with at the interpersonal level, with an 
emphasis on securing shared meanings and under-
standings of their subjective experience (Mosher 
1975). Overarching and all-encompassing theories 
of disease, professionally acquired belief systems 
and practices, and the chemical alteration of con-
sciousness by antipsychotic drugs are all considered 
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Facility
Small and community-based•	
Open, voluntary and home-like•	
Sleeps no more than ten people, including two •	
staff (one man and one woman)
24–48 hour shifts to allow prolonged intensive •	
one-to-one contact
Social structure
Preserves personal power, to preserve autonomy, •	
diminish the hierarchy in the facility, prevent the 
development of unnecessary dependency and 
encourage reciprocal relationships
Minimal role differentiation (between staff •	
and residents) to encourage flexibility of roles, 
relationships and responsibilities
Daily running of the facility is shared as much •	
as possible. Residents do the cooking, cleaning, 
shopping, etc. to maintain attachments to 
ordinary life
Staff
May be mental health professionals, specifically •	
trained and selected non-professionals, 
former clients (particularly those treated in the 
programme) or a combination of all three
Relationships
Staff remain ideologically uncommitted •	
Convey positive expectations of recovery•	
Validate residents’ subjective experience of •	
psychosis as real by developing an understanding 
of it through spending time with and doing 
activities with them
Avoid psychiatric jargon in interactions with •	
residents
Therapy
All activities viewed as potentially therapeutic •	
but without formal therapy sessions 
In-house problems dealt with immediately by •	
communal problem-solving sessions
Medications
No or low-dose antipsychotic drug use•	
Benzodiazepines may be used in the short term •	
to help restore sleep/wake cycles
Length of stay
Sufficient time spent in the programme for •	
residents to develop relationships that allow 
precipitating events to be acknowledged, and 
painful (and potentially disavowed) emotions to 
be experienced, expressed and understood in the 
context of the residents’ lives
Aftercare
Post-discharge relationships encouraged (with •	
staff and peers) to allow easy return to the 
facility (if necessary) and to foster development 
of peer-based, problem-solving, community-
based social networks
Box 2 The Soteria critical elements
barriers to this process (Mosher 2004a). To this end 
the ethos of the original Soteria house repudiated 
the conventional biomedical approach (and in fact 
distanced itself from any consistent ideological 
framework). The treatment facility was a suburban 
house staffed by non-professionals trained to tend 
to people at the limits of human experience without 
succumbing to the usual assumptions and preju-
dices (Mosher 1973). The facility used contextual 
constraints to engender a defined and predictable 
social environment within which so-called inter-
personal phenomenology could be practised 
(Box 3). Finally, and perhaps most importantly for 
the purposes of this critique, the use of antipsychotic 
medication was marginalised, and ordinarily such 
drugs were not prescribed for at least the initial 
6 weeks of treatment (Mosher 1975).
All of the above would perhaps be of limited 
interest to modern psychiatry were it not for the 
systematic and sustained empirical evaluation of 
the paradigm’s efficacy that has been under taken 
over the almost 40 years since its inception (Calton 
2008). 
Testing the paradigm
Three randomised controlled trials of the efficacy of 
the Soteria paradigm have been conducted: two in 
the USA (Bola 2003) and one in Switzerland (Ciompi 
1992). The 223 participants (179 in the USA study, 
and 44 in the Swiss) were diagnosed with first- or 
second-episode schizophrenia-spectrum disorders. 
These studies compared people treated in Soteria 
Box 3 Creating the Soteria environment
Contextual constraints
Do no harm•	
Treat everyone, and expect to be treated, with dignity •	
and respect
Guarantee sanctuary, quiet, safety, support, protection, •	
containment and interpersonal validation
Ensure food and shelter•	
Create an atmosphere imbued with hope – recovery •	
from psychosis is expected and is possible without 
antipsychotic drugs
Interpersonal phenomenology
Focus on developing a non-intrusive, non-controlling •	
but actively empathic relationship with residents by 
just spending time with them, without having to do 
anything explicitly therapeutic or controlling. The aim is 
to develop a shared experience of the meaningfulness 
of the resident’s individual social context, both current 
and historical
communities with people who received treatment 
as usual (TAU), meaning hospital admission and 
treatment with antipsychotic medication. These 
have generated a considerable secondary literature, 
with 76 citations currently identifiable (Calton 
2008). The US trials found that at 6-week follow-
up there were significant and similar improvements 
in global psychopathology in both the Soteria 
group and the TAU group, even though only 24% 
of the Soteria group had received any antipsychotic 
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medication (and only 16% of these had received 
drug treatment for longer than a week). Multi variate 
analysis of 2-year follow-up data found significantly 
greater improvements in global psychopathology 
and ‘composite outcome’ (an eight-item assessment 
including employment and social functioning; 
Bola 2002) significantly more participants living 
independ ently, and significantly fewer readmissions 
for the Soteria group compared with the TAU 
group (Bola 2003). In addition, only 34% of the 
Soteria group had taken antipsychotic medication 
(continuously or intermittently), compared with 
95% of the TAU group (43% of the Soteria partici-
pants had taken no antipsychotic medication at 
all). Only 59% of the Soteria group had received 
psychiatric treatment, compared with 100% of those 
in treatment as usual (Warner 1997). 
The Swiss trial reported outcomes on a range of 
measures, including the Brief Psychiatric Rating 
Scale, housing and employment status, global 
outcome, global autonomy, relapse rate and average 
medication dose (Ciompi 1992). At 2-year follow-
up, TAU and Soteria participants demonstrated 
similar levels of psychopathology and functioning, 
with the Soteria group using significantly lower 
doses of antipsychotic medication (25% less during 
the acute treatment phase and 50% less overall). 
Both the US and Swiss studies reported longer 
stays in the Soteria communities than in hospital, 
but additional costs were offset by the much lower 
prevalence of antipsychotic use, not to mention the 
reduced ‘personal’ costs of not using medication. It 
must be borne in mind that there is no evidence 
to suggest that the three iterations of the Soteria 
paradigm cost more than treatment as usual, and 
some limited evidence to show that they cost less 
(Ciompi 2004). 
The Finnish collaborative studies
From 1967, Yrjo Alanen and colleagues in Turku, 
Finland, developed a primarily psychosocial 
approach to the care of people diagnosed with early 
schizo phrenia. This need-adapted or integrated 
approach is fast becoming the standard treatment 
for schizophrenia in Finland (Mosher 2004a) and 
is based on several core principles (Alanen 1991), 
some of which are given in Box 4. It could be argued 
that this represents a holistic approach to care and, 
although antipsychotic medication was used, the 
original model advocated withholding drugs for an 
initial 3-week assessment period to enable psycho-
socially informed recovery. 
The Acute Psychosis Integrated Treatment Project, 
which began in 1992, specifically addressed the 
issue of medication (Lehtinen 2000). It involved six 
study centres (all of which stuck to the need-adapted 
model), three of which employed a no or low-dose 
antipsychotic drug approach after an initial 3-week 
antipsychotic-free period (experimental group), with 
the remainder using antipsychotics at recommended 
therapeutic doses (control group). The study enrolled 
106 participants (67 experimental and 39 control 
– the majority diagnosed with schizophrenia). 
Whole-cohort analysis after 2 years showed that 
41% had spent less than 2 weeks in hospital over 
the study period, 52% had experienced no psychotic 
symptoms in the previous year and 40% had Global 
Assessment Scale (GAS) scores of 70 or more 
(suggesting relatively good global functioning) 
(Endicott 1976). Employment data showed that 
47% were working, which is interesting given that 
US data have suggested that only 15–20% of people 
diagnosed with schizophrenia are working 2 years 
after admission (Mosher 2004a). In the experimental 
group, 43% had never taken antipsychotic 
medication, whereas the corresponding figure for 
the control group was 6%. The experimental group 
had received significantly less hospital treatment 
and had experienced fewer psychotic symptoms 
during the previous year (Lehtinen 2000). 
Further study
An iteration of the need-adapted approach con-
ducted in Sweden reported results similar to those 
achieved with treatment as usual, but at about half 
of the direct economic costs (Cullberg 2002, 2006). 
Jaakko Seikkula and colleagues in Oulu, Finland, 
have further refined the need-adapted approach 
(Mosher 2004a). Their open-dialogue family and 
network approach (Seikkula 2006) aims to treat 
people diagnosed with schizophrenia in their own 
homes. The treatment involves the service user’s 
social net work and starts within the first 24 hours 
of initial contact, with the general aim of generating 
a constructive dialogue with the person and their 
family in an effort to find personally meaningful 
Box 4 Core principles of the need-adapted approach
Flexible and individually tailored therapeutic interventions designed to meet the needs of •	
service users and their families, with an emphasis on developing shared understandings of 
their subjective experiences
Using a predominantly psychotherapeutic attitude towards examination and treatment, •	
emphasising an attempt to understand what has happened and is happening to the service 
users and their significant others
The various therapeutic activities deployed should complement each other. Teamwork, •	
cooperation and good communication are central
Treatment is considered a work in progress and not an end in itself. Therefore, continuity •	
of care, together with critical thinking and reflexive (recursive) thought, illuminating the 
circular relationship between cause and effect, are emphasised
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understandings of their experiences. People diag-
nosed with schizophrenia and treated using 
this version of the need-adapted approach had 
significantly fewer relapses and residual psychotic 
symptoms, were more likely to be employed, 
spent significantly less time in hospital and used 
antipsychotics significantly less often than people 
exposed to treatment as usual (Seikkula 2003). 
uS studies
From the 1950s until the late 1970s a series of studies 
concerning the treatment of schizophrenia with or 
without antipsychotic medication was conducted in 
the USA (Wirt 1959; Pasamanick 1967; Schooler 
1967; Klein 1973; Carpenter 1977; Goldstein 1978; 
Rappaport 1978; May 1981). Most were placebo-
controlled immediate assignment studies that used 
only antipsychotic medication in their experimental 
cohorts (and thus did not attempt to treat the whole 
person). For the purposes of this review only two 
bear further scrutiny: the studies conducted by 
William Carpenter and colleagues at the US National 
Institute of Mental Health in Maryland (Carpenter 
1977) and by Maurice Rappaport and colleagues 
at the St Agnews State Hospital in California 
(Rappaport 1978). Both are of note because, unlike 
the others, they used specially designed therapeutic 
(albeit hospital-based) milieus that emphasised 
self-understanding, social adaptation, tolerance 
of bizarre behaviour, interpersonal support and a 
willingness to give considerable time and attention 
to a person going through crisis. 
In the Carpenter study, 49 people diagnosed 
with ‘good-prognosis schizophrenia’, a record of 
adequate prior work and social functioning, and 
a short history of illness, were arbitrarily assigned 
by their psychiatrist to treatment with or without 
antipsychotic medication (Warner 1997). There 
were no differences between the two groups with 
regard to their prognostic ratings and initial clinical 
characteristics. At 1-year follow-up the people 
assigned to the no-medication arm spent significant-
ly less time in hospital (108 days compared with 
126 days) and were significantly less likely to be 
readmitted (35% v. 45%) or be treated with drugs 
(44% v. 67%) during post-discharge follow-up 
(Carpenter 1977). 
In the Rappaport study, 80 young men with a 
diagnosis of acute schizophrenia were randomly 
assigned on admission to either antipsychotic 
medica tion or a placebo, with both groups being 
exposed to the same therapeutic milieu. At 3-year 
follow-up, 73% of the medicated group had been 
readmitted to hospital, compared with 8% of those 
originally given a placebo and thereafter never 
medicated. The authors concluded that ‘anti-
psychotic medication is not the treatment of choice, 
at least for certain patients, if one is interested in 
long-term clinical improvement’ (Rappaport 1978). 
This tradition of research stimulated a long-standing 
debate concern ing the ethics of medication-free 
research into the treatment of schizophrenia, which 
continues to this day (Rothman 1994; Carpenter 
1997a; Fins 1997; Wyatt 1997; Moser 2005; Bola 
2006). The consen sus appears to be that such 
research is not associated with widespread problems 
of informed consent or adverse conse quences to 
patients and is ethically justifiable in the search for 
new treatments (Carpenter 1997b; Bola 2009).
Beyond medication, beyond psychiatry  
and beyond psychosis
Where would you turn if you went to the limits 
of human experience, experiencing ‘madness’ and 
potentially extreme distress? One of us (T.C.) con-
fronted this question recently when he experienced 
an episode of what could be called psychosis. What 
follows is a personal account of certain aspects of 
that experience. This opening up of experience is 
intended to provide a personal and thus necessarily 
subjective perspective on this debate and, in doing 
so, perhaps return it to its starting point: the partic-
ularity of human experience understood in its wider 
material, historical and social context.
Personal experience: Tim Calton
The question feels quite easy to answer; I would not 
engage with psychiatric services and, in fact, would 
do my best to stay as far away as possible from them. 
These experiences came about in a particular context 
and for particular reasons, and I would not want them 
dishonoured by being forced to understand them as 
figments of an imagined illness. The one-size-fits-all 
approach to understanding and treating madness is 
anathema to me: where is the room for thought about 
personal crises, the influence of past and current 
stress, and just different ways of seeing the world in 
the monolith of psychosis/schizophrenia? Hearing 
voices did not bother me, though the experience of 
my thoughts being available to everyone in the room, 
the lurching inversion of the utterly private into the 
public, was terrifying beyond belief and led to what I 
can only describe as a stupor; I was literally paralysed 
with fear. More insidious was the thought that those 
people who purported to love and like me were lying, 
perhaps even plotting against me. It felt like falling 
off the calendar. I think it speaks volumes about 
their capacity to tolerate difference, idiosyncrasy, 
and uncertainty that we were able to find a way 
through those moments in the abyss together, without 
recourse to such deadening concepts as ‘psychosis’ 
and ‘schizophrenia’ and certainly without the need 
for chemical sanitation. That the people who helped 
in those moments were psychiatrists is an irony not 
lost on me (or them). That I was very fortunate to be 
with people with a capacity to tolerate the extreme 
nature of the situation is something I reflect on (and 
am grateful for) every day. I think the lack of treatment 
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choices for people diagnosed with schizophrenia and/
or experiencing psychosis is abject and shames our 
profession.
Conclusions
Even the most conservative analysis of the data 
pre sented above would probably concede that it 
may be possible to treat people diagnosed with 
first- or second-episode schizophrenia by using 
psycho socially oriented therapeutic milieux and 
minimal or no antipsychotic medication at least as 
effectively, and at no more fiscal cost, than standard 
care. That said, it is abundantly clear that most of 
the stud ies cited included only people diagnosed 
with early schizophrenia, did not use a randomised 
controlled methodology (currently regarded as the 
gold stan dard for evaluating treatment efficacy in 
psychiatry), had small numbers of participants 
and used an ostensibly heterogeneous array of 
therapeutic milieux. However, this article was never 
intended to convince the psychiatric profession of 
the absolute rectitude of our position or argue that 
these approaches be adopted wholesale. We instead 
hope to open up a space in which the option of 
minimal or no medi cation approaches to treating 
schizophrenia can be considered and discussed here 
in the UK. Such openness is necessary in order to 
support those psy chiatrists currently attempting 
to treat people who do not agree with a medical 
understanding of their experiences. Given that 
patient choice will remain an essential component 
of National Health Service policy (Department of 
Health 2008), yet is so absent in the treatment of 
schizophrenia in the UK, and in light of the fact that 
we are already being left behind by several of our 
European neighbours with respect to alternative 
provision, perhaps the time for this discussion is 
now upon us.
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MCQs
The following was or is a UK-based no- or 1 
minimal-medication approach to treating 
schizo phrenia: 
the Soteria paradigma 
the Geel ‘family boarding’ systemb 
need-adapted treatmentc 
the open-dialogue approachd 
Villa 21.e 
The social-structure element of the Soteria 2 
paradigm includes: 
a clearly defined hierarchya 
daily activities defined and controlled by staffb 
curtailment of personal power and autonomyc 
at least weekly contact with medical staffd 
minimal rules and structures imposed.e 
Features of a Soteria environment include: 3 
submission to medical authoritya 
expectation of recovery from schizophrenia but b 
only with the use of antipsychotic medication
reducing the residents’ ability to influence their c 
immediate environment
treating everyone with dignity and respectd 
employing a token economy to maintain order.e 
Interpersonal phenomenology involves: 4 
rigid adherence to psychodynamic principlesa 
avoiding discussing the subjective reality of a b 
person’s psychotic experiences
reference to cognitive–behavioural theoryc 
‘being with’ not ‘doing to’ (the person in distress)d 
playing down the importance of a client’s e 
individual social context.
Need-adapted treatment includes the 5 
following core principle: 
developing shared understandings of the a 
subjective experience of the service user
using a predominantly biomedical approach to b 
examination and treatment
employing a disparate array of therapeutic c 
activities, which do not necessarily complement 
each other 
diagnosis and treatment are ends in themselves d 
the involvement of the family is of marginal e 
interest. 
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